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Role of the JNK pathway in NMDA-mediated
excitotoxicity of cortical neurons
C Centeno1,8, M Repici1,8, J-Y Chatton2, BM Riederer1,3, C Bonny4, P Nicod5, M Price1, PGH Clarke1, S Papa6,
G Franzoso6 and T Borsello*,1,7
Excitotoxic insults induce c-Jun N-terminal kinase (JNK) activation, which leads to neuronal death and contributes to many
neurological conditions such as cerebral ischemia and neurodegenerative disorders. The action of JNK can be inhibited by the D-
retro-inverso form of JNK inhibitor peptide (D-JNKI1), which totally prevents death induced by N-methyl-D-aspartate (NMDA) in
vitro and strongly protects against different in vivo paradigms of excitotoxicity. To obtain optimal neuroprotection, it is
imperative to elucidate the prosurvival action of D-JNKI1 and the death pathways that it inhibits. In cortical neuronal cultures, we
first investigate the pathways by which NMDA induces JNK activation and show a rapid and selective phosphorylation of
mitogen-activated protein kinase kinase 7 (MKK7), whereas the only other known JNK activator, mitogen-activated protein
kinase kinase 4 (MKK4), was unaffected. We then analyze the action of D-JNKI1 on four JNK targets containing a JNK-binding
domain: MAPK-activating death domain-containing protein/differentially expressed in normal and neoplastic cells (MADD/
DENN), MKK7, MKK4 and JNK-interacting protein-1 (IB1/JIP-1).
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In many nervous system disorders, including cerebral
ischemia, traumatic brain injury and neurodegenerative
diseases, overactivation of N-methyl-d-aspartate (NMDA)
receptors leads to neuronal damage, resulting in neuronal
loss and consequent severe neurological impairment. This
cascade of neuronal injury, referred to as ‘excitotoxicity’, is still
only partly understood. Dying neurons activate complex signal
transduction events to trigger their death program, and the
c-Jun N-terminal kinase (JNK) pathway plays an important
role in this process.1
D-retro-inverso form of JNK inhibitor (D-JNKI1) is an
extremely potent neuroprotectant against excitotoxicity of
cortical neurons and against different in vivo paradigms of
neurodegeneration.2–4 The active part of this peptide contains
a retro–inverso form of a 20-amino-acid sequence (JBD20)
from the JNK-binding domain (JBD) of the scaffold protein
JNK-interacting protein-1 (IB1/JIP-1), and it blocks the access
of JNK to many of its targets.5–7 Recently, Negri et al.8,9
performed a detailed re-examination of the JBD-containing
proteins and identified 19 different substrates of JNK. They
then proved in a cell-free assay that the JBD20 sequence
prevented interactions and phosphorylations by JNK of nine of
these targets. Among these nine substrates, we have studied
the following four that might participate in regulating the death
of cortical neurons: (1) MADD/DENN (MAPK-activating death
domain-containing protein/differentially expressed in normal
and neoplastic cells); (2–3) mitogen-activated protein kinase
kinase 4 (MKK4) and mitogen-activated protein kinase kinase
7 (MKK7), the two direct upstream activators of JNK and (4)
the scaffold protein IB1/JIP-1.
In particularly, MADD/DENN was identified as a substrate
for JNK3,10 the isoform most clearly involved in excitotoxi-
city11,12 and mostly expressed in the brain.10–12 Increasing
evidence supports a strong correlation between low MADD/
DENN expression and neuronal loss.13,14
MKK4 and MKK7 are the only known JNK activators. In
some cell types, MKK4 activates JNK primarily by stress
stimuli and MKK7 by inflammatory cytokines15–17 but in
neuronal excitotoxicity their contributions are still not known.15
Both MKK48,9,18 and MKK78,9 have a JBD indicating that
these activators of JNK are also targets and potentially
sensitive to D-JNKI1.
Finally, the scaffold protein IB1/JIP-1 itself presents a
JBD20 domain: it plays an important role in organizing the JNK
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cascade and shows a tight relationship with cell death. IB1/
JIP-1 can influence JNK signalling both positively and
negatively, depending on the amounts of IB1/JIP-1 and its
interacting kinases.19–21
Our aim is to identify the critical features of the powerful
protective action of the D-JNKI1 peptide and to examine
JNK targets in excitotoxic neuronal death pathways. This
can offer important clues to produce new inhibitors of
excitotoxicity.
Results
Phase contrast microscopy indicated that exposure of
neurons to 100mM NMDA induced immediate (within 1 h)
marked swelling of neuronal cell bodies, followed by total
neuronal degeneration over the next 48 h (97% cell death at
48 h, as reported previously by Borsello et al.6).
Dying neurons were visualized with propidium iodide (PI,
2mg/ml, 5 min). Morphological observation of control cultures
indicated the presence of very few apoptotic neurons (cellular
shrinkage and punctate staining, indicating clumping of
chromatin in a condensed nucleus, see Figure 1a). D-
JNKI1-protected neurons presented hardly any apoptotic
bodies such as control (Figure 1b) and this clearly contrasted
with NMDA-treated cultures where most neurons were
necrotic (nuclei stained uniformly with PI, Figure 1c). In our
model, all neurons received the excitotoxic stimulus at the
same time but death was not tightly synchronized: some
neurons died early, others late – a fact that has been analyzed
in some details in the context of excitotoxicity.22
NMDA-induced changes in Ca2þi in control neurons
compared to D-JNKI1-treated neurons. We first analyzed
the molecular events underlying excitotoxic signalling
induced by NMDA, and the protective effects of D-JNKI1,
from the cell surface through the cytoplasm to the nucleus.
We started by checking whether D-JNKI1 affected the
normal functioning of the NMDA receptor, monitoring the
Ca2þi response to NMDA stimulation of cortical neurons by
fluorescence microscopy using the Fura-2 probe. Exposure of
cortical neurons to 10 or 100mM NMDA markedly raised the
intracellular Ca2þ concentration in control neurons (Figure
1e–g). In D-JNKI1 pretreated neurons, this stimulation
resulted in similar Ca2þi responses to those in control neurons
(Figure 1i–m). In four independent experiments, the propor-
tion of neurons responding to the stimulus was the same in the
control group (20 responders/41 total) and in the D-JNKI1-
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Figure 1 Morphological observation of neuronal death (a–c). Phase contrast
microscopy of cortical neuronal morphology, scale bar, 60 mm. In control cultures,
very few neurons presented apoptotic nuclei visualized by PI staining as shown at
higher magnification in the inset scale Bar, 5 mm (a). The NMDA-treated cultures
presented strong sign of necrosis: arrows indicated swollen neurons, containing
enlarged nuclei. The necrotic nuclei are stained uniformly with PI (c). NMDA-treated
cultures protected by D-JNKI1 presented control morphology (b) without any
necrotic features and as in the control condition PI hardly labeled only a very few
cells with apoptotic features. Effect of D-JNKI1 on NMDA-induced changes in Ca2þ
(d–m). Control neurons visualized by interference contrast microscopy. Scale bar,
20mm (d). Image of Fura-2-loaded neurons recorded under basal conditions (e).
Ca2þ response to NMDA stimulation after stimulation with 10 and 100mM NMDA.
Intracellular Ca2þ responses range from blue to red for elevated values (f). Cortical
neurons were pretreated with 2mM D-JNKI1 and visualized by interference contrast
microscopy (h). The same Fura-2-loaded neurons are shown in the basal condition
(i) and after exposure to 10 and 100mM NMDA (l). Intracellular Ca2þ response
shows normal behavior in the presence of D-JNKI1. The plots present Ca2þ traces
from selected cells in (g) the control group of neurons (n¼ 41 cells from two
experiments) and (m) the D-JNKI1-treated group (n¼ 44 cells from three
experiments)
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treated group (21 responders/44 total). In non-treated
neurons responders, the amplitude of the Ca2þi response
was respectively 5367127 and 3767130 nM after applica-
tion of 10 and 100mM NMDA. The amplitude of the
Ca2þi responses of D-JNKI1-treated neurons responders
was not significantly different from the non-treated cells and
averaged 357757 nM (P¼ 0.199) and 443782 nM (P¼
0.662). Therefore, D-JNKI1 does not significantly affect the
function of the NMDA receptor or its associated Ca2þi response.
Excitotoxic signalling pathway in cortical neurons. To
better characterize NMDA-induced neuronal death of cortical
neurons, we tested whether different inhibitor combinations
would prevent it.
The addition of 1–3mg/ml of cycloheximide to neuronal
cultures efficiently inhibited protein synthesis more than 90%
(data not shown), but adding it before the NMDA gave no
protective effect on neuronal loss (Figure 2a). Neuronal death
was assessed after 5 h by lactate dehydrogenase (LDH)
release into the bathing medium as described previously.6 We
used a combination of cycloheximide and D-JNKI1 given
before NMDA stress, and the peptide still provided total
protection after 5 h (Figure 2a). We then examined whether
the broad-spectrum caspase inhibitor z-Val-Ala-Asp fluoro-
methylketone (z-VAD.fmk) partially reduced NMDA-induced
death (Figure 2b). Addition of 150 or 300mM of z-VAD.fmk to
neuronal cultures before NMDA treatment efficiently inhibited
caspase-3 activation (Figure 2c) but did not block death
measured after 5 h by LDH (Figure 2b). Although the caspase
inhibitor alone did not prevent induced neuronal death,
D-JNKI1 did prevent caspase-3 activation (Figure 2c).
As NMDA-induced death persisted with the protein synth-
esis inhibitor and with the caspase inhibitor alone, blocking
only one pathway is not enough to prevent neuronal loss.
However, D-JNKI1 conferred total protection even in the
presence of the protein synthesis inhibitor. We tried a
combined treatment with z-VAD.fmk and cycloheximide to
prevent NMDA-induced death, and it did provide 60%
neuroprotection (Figure 2d). It thus appears that NMDA
activates at least two different death pathways, one indepen-
dent of protein synthesis and the other dependent on it. In the
first, post-translational modifications of pre-existing proteins
are taking part in the death process and are associated with
the JNK action. The second pathway depends on protein
synthesis, owing to the well-known activation of transcription
factors such as c-jun,11,13,23 ATF2, Elk-1 and c-fos induc-
tion.6,8,9,24
To identify the nature of the death pathway not blocked by
z-VAD.fmk and cycloheximide but inhibited by D-JNKI1, we
studied the JBD–containing non-transcription factor targets
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Figure 2 Inefficacy of caspase inhibitor cycloheximide against NMDA-induced
neuronal death. Cycloheximide is ineffective against NMDA-induced excitotoxicity,
but either alone or with cycloheximide D-JNKI1 protects cortical neurons against
NMDA at 5 h (a). Effect of z-VAD.fmk and 2mM D-JNKI1 on neuronal death as
assayed by LDH release after 5 h NMDA exposure, z-VAD50: 50 mM z-VAD.fmk; z-
VAD150: 150mM z-VAD.fmk; ZVAD300: 300mM z-VAD.fmk (b). Effect of z-
VAD.fmk and D-JNKI1 on pro-caspase-3 cleavage: in Western blot anti-caspase-3
antibodies reveal both pro-caspase-3 and the cleaved p12 product (c). Protective
effect of the combined treatment with z-VAD.fmk and cycloheximide. The joint
treatment provides 60% neuroprotection against NMDA. Neuronal death was
measured with LDH release at 24 h (d). Quantifications were performed in 10
independent experiments (7S.E.M.)
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whose post-translational modifications are related to JNK
phosphorylation and inhibited by JBD20 in cell-free competi-
tive assay.8,25
MADD/DENN role in excitotoxicity and the effect of
D-JNKI1. To study MADD/JNK interaction, we first performed
in vitro kinase assays with MADD substrate produced as
glutathione S-transferase (GST) fusion proteins. Recombinant
JNK2 and JNK3 protein kinases were incubated with [g-
33P]ATP, the constructed GST-MADD fusion proteins and
either with JBD20 or JBDmut for 30 min.
As shown in Figure 3g, JNK2 and JNK3 specifically
associate10 with and phosphorylate MADD/DENN. No phos-
phorylation was detected for both isoforms in the presence of
the retro–inverso JBD20 peptide, whereas the control mutated
peptide JBDmut
2,8 had no effect.
We then analyzed the expression of MADD in response to
NMDA and the effect of D-JNKI1 by immunofluorescence and
Western blots in cortical neurons. In control conditions, MADD
staining was sparse and diffusely distributed in the cytoplasm
of neurons (Figure 3a, d), whereas after 1 h of NMDA
treatment MADD was strikingly relocalized into the nuclei
and nucleoli of dying neurons (Figure 3b, e: MADD colocalizes
with DAPI, N.B.: here DAPI is more intensely and uniformly
labeled). The nuclear translocation of MADD was mostly
prevented by D-JNKI1 pretreatment (Figure 3c–f).
To further characterize the changes in MADD expression,
we studied it during NMDA treatment from 5 min to 5 h in
Western blots of total cortical neuronal extracts. The level of
MADD fell rapidly after NMDA; there was a clear effect after
only 15 min and at 5 h the decrease was 80% (Figure 3h).
We investigated whether calpains or the ubiquitin-proteo-
lytic pathway are implicated in the MADD degradation
mediated by NMDA. For this purpose, cortical neurons were
pretreated with calpastatin, a specific calpain inhibitor, and
with two potent proteasome inhibitors: lactacystin (20S
proteasome inhibitor) and MG132 (against the 26S complex).
Western blotting showed that MADD degradation was
unaffected by calpastatin (Figure 3i) but was strongly inhibited
by both proteasome inhibitors, lactacystin and MG132 (Figure
3j, k). These data prove that calpains are not involved in
MADD degradation, whereas the proteasome pathway is
responsible for it following NMDA treatment. However,
inhibition of MADD degradation through the proteasome did
not protect neurons from death (data not shown). D-JNKI1
also prevented MADD degradation like lactacystin and
MG132 (see Figure 3j, k), whereas with z-VAD.fmk/cyclo-
heximide there is no protection.
Responses of MKK7 and MKK4 to NMDA and the effects
of D-JNKI1. We attempted first to document the NMDA-
induced changes in expression and phosphorylation of MKK4
and MKK7 and the effects of D-JNKI1. As both MKK4 and
MKK7 contain a JBD20 homology domain,
8,18,25 they are not
only JNK activators but also substrates and their
phosphorylation by JNK is likely to be sensitive to D-JNKI1.
In the time course (from 10 min to 5 h) of the NMDA effect on
total extracts of cortical neurons, the MKK7 level deeply
declined (90%) in the first 10 min, whereas the decrease in
MKK4 was weaker and reached 90% only after 5 h of NMDA
(Figure 4a and Supplementary Figure).
To assess the changes in their subcellular localization, we
performed an immunofluorescence analysis and a fraction
separation. Nuclear and cytoplasmic fractions of control and
NMDA-treated neurons were charged and blotted for MKK7
and MKK4 (Figure 4b). In the control condition, MKK7 was
distributed in both the cytoplasm and nucleus, but exposure to
NMDA caused a massive translocation of MKK7 into neuronal
nuclei (Figures 4b and 5). In contrast, MKK4 was mainly
cytoplasmic, and NMDA caused no changes in its distribution
in the first hours of treatment (Figures 4b and 6). Only at 5 h of
NMDA exposure it was possible to detect scant traces of
MKK4 in the nuclear fraction using the anti-MKK4 antibody
from Upstate (no. 07–194; see Materials and Methods). We
repeated this experiment using a second antibody (from
Santa-Cruz, see Coffey et al.26), but were still not able to
detect an increase of MKK4 in the nuclei after NMDA
stimulation.
We then evaluated the effect of NMDA on the degradation
and translocation of MKK7 by immunofluorescence. In control
neurons, MKK7 staining was typically punctate in the
perikaryal cytoplasm (Figure 5a, d) and sometimes a nuclear
pool of MKK7 was also detectable (Figure 5b, e). After 1 h of
NMDA stimulation, the staining was localized almost exclu-
sively in the nuclei of the stressed neurons (Figure 5c, f).
D-JNKI1 largely prevented this nuclear translocation (as
Figure 3 MADD/DENN in excitotoxicity. Immunofluorescence study (a–f): neurons are labeled with anti-MADD/DENN antibody (a, b and c) and nuclei are counterstained
with DAPI (d, e and f). In control condition, the staining of MADD/DENN is cytoplasmic (a) but after NMDA treatment MADD is also present in the nuclear compartment and
colocalizes with DAPI (b, arrow and e). NMDA-treated neurons show a more strongly labeled nucleus with DAPI than control ones, and dying neurons are easily identifiable
(e). D-JNKI1 pretreatment prevents MADD translocation within nuclei (c) and DAPI reveals very few intense and uniformly stained nuclei (f). Scale bar, 10mm. In vitro JNK
competitive assay showing specificity of the JNK inhibitor peptide (g): kinase assays with recombinant activated JNK2 and -3, using GST-MADD as substrate as described
previously.5,6 The JBD20 peptide inhibits MADD phosphorylation whereas the control-mutated peptide JBDmut has no effect. Western blot study (h) of MADD/DENN after an
NMDA time course on total extracts of cortical neurons, with the corresponding quantification. The MADD/DENN-reactive band atD200 kDa decreases immediately after
5 min of treatment and at 15 min of NMDA exposure presents a reduction of 90%. MADD degradation pathways following NMDA (i–k). In (i), cortical neurons were pre-treated
with 5 and 10mM calpastatin peptide for 1 h and incubated with NMDA for 5 h. Calpain inhibitor has no effect on MADD degradation, whereas D-JNKI1 strongly prevents it. The
Western blot densitometry clearly proves that calpains are not involved in MADD degradation. Proteasome inhibitors (j–k): the lactacystin proteasome inhibitor (against the
20S complex) was tested and compared with the D-JNKI1 effect on MADD degradation (j). The lactacystin prevents MADD degradation induced by NMDA in a dose-
dependent way, D-JNKI1 protects as well. MG132, the second proteasome inhibitor (of the 26S complex), was tested in parallel with the two neuroprotective treatments (k): D-
JNKI1 (2 mM) and z-VAD.fmk/cycloheximide (150–300 mM, see Figure 2). Western blot analysis and quantification demonstrates that MG132 powerfully prevented MADD
degradation. Both MG132 and D-JNKI1 preserve a level of MADD comparable to the control condition, whereas the z–Vad.fmk/cycloheximide has no effect. Quantifications
were performed in five independent experiments (7S.E.M.)
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shown in Figure 5g, h i and j). Using fraction separation
Western blotting this effect is more appreciable and measur-
able (Figure 5k, l). The peptide entirely prevented the
decrease in cytoplasmic MKK7 from 5 min to 1 h of NMDA
treatment and even at 5 h D-JNKI1 still prevented 50% of the
decrease (Figure 5k, l).
For MKK4 immunofluorescence, only the Santa-Cruz anti-
body was utilizable: the labelling was equally distributed in
nuclei and cytoplasm in control conditions as well as after
NMDA stimulation, without any changes in localization
throughout the 5 h examined (Figure 6a–f). In Western blot
studies, D-JNKI1 blocked the NMDA-induced decrease in
MKK4 level (Figure 6i, j).
Activation of MKK7 and MKK4 after NMDA
stimulation. To determine to what extent MKK4 and
MKK7 contribute to JNK activation after NMDA stress, we
analyzed their phosphorylation in the first hours of NMDA
treatment. In this model, maximal JNK activation occurs in
the first hour of NMDA treatment, followed by a decrease6
and it is reasonable to expect a prior phosphorylation of the
two direct upstream JNK activators.
We looked at P-MKK4 and P-MKK7 forms from 5 min to 5 h
after NMDA exposure (Figure 4c,d).
As clearly shown in Figure 4c and d, NMDA caused a
striking increase in MKK7 phosphorylation in the first 30 min of
stimulation, whereas no increase in phosphorylation of MKK4
was detectable, and the level of P-MKK4 in fact decreased
progressively to virtually zero (Figure 4d).
To examine and quantify more exactly the activation of
these two proteins, we did additional studies involving
immunoprecipitation with the P-MKK7 and P-MKK4 anti-
bodies. P-MKK7 and P-MKK4 were immunoprecipitated at 10,
20, 30 min and at 5 h of NMDA stimulation, from nuclear and
cytoplasmic fractions.
The results confirmed that MKK7 was powerfully activated
by NMDA in the nuclear fraction, with maximal activation after
10 min (Figure 4e, g), as revealed previously by Western blot
(Figure 4c, d). MKK7 activation by NMDA returned to basal
levels by 40 min (mirroring the JNK response reported in this
model).
Immunoprecipitated P-MKK7 was quantified with densito-
metry analysis and the maximal activation was four-fold
higher than the basal (control) level (Figure 4g). The
immunoprecipitation experiments also confirmed that MKK4
activation was unaffected by NMDA at all time points and that
it remained almost exclusively cytoplasmic (Figure 4f and h).
Thus, NMDA selectively activated MKK7, whereas MKK4 was
unaltered.
Effect of D-JNKI1 on P-MKK7 and P-MKK4
activation. We tested whether D-JNKI1 (2 mM as in all the
presented experiments) affects NMDA-induced activation/
phosphorylation of the two kinases. We examined MKK7
activation after 10 min NMDA stimulation as at this time point
MKK7 phosphorylation was maximal. Pretreatment with D-
JNKI1 did not affect the level of P-MKK7 (Figure 4i). We also
analyzed the effect of D-JNKI1 effect on P-MKK4: as shown
before MKK4 presented its maximal activation in control
condition. As for MKK7, D-JNKI1 did not affect the
phosphorylation of MKK4 (Figure 4j).
Role of IB1/JIP-1 in excitotoxicity and the effect of
D-JNKI1. We investigated IB1/JIP-1 modifications in NMDA-
induced death and the inhibitory action on it of D-JNKI1.
Immunofluorescence showed that in the control condition,
IB1/JIP-1 was almost exclusively in axons and as weak
spots in the neuronal soma (including some nuclei)
(Figure 7a), whereas after NMDA treatment it became
strongly nuclear in the first hour of treatment (Figure 7c). D-
JNKI1 pretreatment prevented the nuclear translocation but
did not preserve the axonal staining characteristic of control
neurons (Figure 7e).
In Western blot analyses of total extracts, the IB1/JIP-1
level had already decreased by 30% after 10 min of NMDA
treatment, and at 5 h it was very weak. Moreover, the single
band seen after short times of treatment had segregated into
two separate bands27,28 (Figure 7g, h and j).
Using fraction separation, the resolution of IB1/JIP-1 was
improved and it was confirmed that in the control condition it
distributed in both nuclear and cytoplasmic fractions, whereas
after excitotoxic (NMDA) stimulation IB1/JIP-1 increased in
the nuclear fraction during the first 20 min before subse-
quently decreasing (Figure 7a–f, h).
In order to clarify IB1/JIP1 interaction with JNK, we
performed in vitro (cell-free) kinase assays with GST-IB1/
JIP1 fusion proteins as a substrate. Activated JNK3 protein
kinase was incubated with [g-33P]ATP, the GST-IB1/JIP1
fusion proteins and either with JBD20 or JBDmut for 30 min. As
shown in Figure 7i, JNK3 phosphorylated IB1/JIP-1. The
Figure 4 Responses of MKK7 and MKK4 to NMDA. Effect of NMDA on MKK4 and MKK7 levels in total extracts (a). MKK7 decreases after 10 min of treatment, whereas
MKK4 is more stable and starts to decrease only at 5 h. Effect of NMDA on fraction extracts (b). In control conditions, there is a pool of MKK7 in both the nuclear and the
cytoplasmic fractions. After NMDA treatment, cytoplasmic MKK7 translocates into the nuclear fraction. To locate MKK4, we tested two antibodies. MKK4 is mainly cytoplasmic
and does slightly increase in the nuclear fraction in response to NMDA. The first antibody used (1st) presents only a nonspecific (ns) band at the wrong molecular weight in the
nuclear fraction. The second one (2nd) shows traces of MKK4 in this fraction. Effect of NMDA on P-MKK7 and P-MKK4 (c, d). MKK7 is activated by NMDA and the activation
arrived at the top at 10 min for then rapidly decreasing at the control level. MKK4 is not activated by NMDA and the excitotoxic stimulation induced a vigorous decrease of P-
MKK4 level. MKK7 phosphorylation assessed by combined immunoprecipitation (anti-P-MKK7-antibody) and Western blotting (anti-total MKK7 antibody) (e).
Immunoprecipitation results were obtained using pools of 10 different dishes and were performed in three independent experiments to quantify the MKK7 activation with
densitometry analysis: there is strong MKK7 activation at 10 min in the nuclear fraction (e, g). MKK4 phosphorylation monitored by combined immunoprecipitation (anti-P-
MKK4-antibody) and Western blotting (anti-total MKK4 antibody) (f). Results are quantified (in h) and MKK4 is not activated at 10 min in the nuclear or the cytoplasmic fraction.
Effects of D-JNKI1 on P-MKK7 and P-MKK4 (i, j). P-MKK7 is activated by NMDA (i) compared to control and the D-JNKI1 treatment (2 mM) does not affect the P-MKK7 level.
P-MKK4 level was analyzed in control condition and D-JNKI1-treated neurons (24 h) do not present any changes in P-MKK4 level (j). Quantifications were performed in eight
independent experiments (7S.E.M.)
Role of JNK activators/targets in excitotoxicity
C Centeno et al
6
Cell Death and Differentiation
CTR 10' 30' 1h 1h 5h10' 30'
MKK7 and MKK4 time-course: on total extracts
5h
MKK7
MKK4
 MKK7 and MKK4 time-course: on fractions
CytoplasmicNuclear
MKK7
MKK4  1st
IP P-MKK7  on fractions IP P-MKK4 on fractions
ns 
P-p47 MKK7 
10' 20' 30' 1h 5hCTR 5' 10' 20' 30' 1h 5hCTR 5'
ns
Nuclear  Cytoplasmic  wo-IP 
ns 
P-p42 MKK4  
CTR 
wo-IP Nuclear  Cytoplasmic  
CTR NMDA10' NMDA10' 
MKK4  2nd
CTR CTR NMDA10' NMDA10' 
100 µM NMDA
100 µM NMDA100 µM NMDA
0
10000
20000
30000
40000
50000
60000
70000
80000
90000
100000
IP P-MKK7 quantification 
CTR CTRNMDA10' NMDA10'
Nuclear Cytoplasmic
0
10000
20000
IN
T'
m
m
2
IN
T'
m
m
2
30000
40000
50000
60000
70000
80000
90000
IP P-MKK4 quantification 
CTR CTRNMDA10' NMDA10'
Nuclear Cytoplasmic
Tubulin
Tubulin
P-MKK4/7 time course
CTR 10' 30' 1h 5h
100 µM NMDA
P-MKK7
P-MKK4
Tubulin
Quantification of P-MKK4/7 time course
CT
R
CT
R D
 -J
NK
I-1
D-JNKI1 effect on P-MKK4 activation
CT
R
NM
DA
 10
’
NM
DA
 10
’/D
-JN
KI1
20' 40'5'
D-JNKI1 effect on P-MKK7 activation
P-MKK7
Tubulin
Tubulin
P-MKK4
P-MKK7 quantification P-MKK4 quantification
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
1.80
2.00
Control  NMDA
5'
NMDA
10'
NMDA
20'
NMDA
30'
NMDA
40'
NMDA
60'
NMDA
5h
P-MKK7
P-MKK4
0
0.5
1
1.5
2
2.5
3
3.5
Control NMDA 10' NMDA10'/D-JNKI1
0
0.2
0.4
0.6
0.8
1
1.2
Control Control/D-JNKI1
R
at
io
 P
-M
KK
4/
Tu
bu
lin
R
at
io
 P
-M
KK
7/
Tu
bu
lin
a
c
e
g
i
b
d
f
h
j
Role of JNK activators/targets in excitotoxicity
C Centeno et al
7
Cell Death and Differentiation
NMDA-MKK7
control-DAPI control-DAPI
CTR CTR 
10'5' 20' 30' 1h 5h
NMDA
D-J
NK
I1
NMDA NMDA NMDA NMDA NMDA
D-J
NK
I1
D-J
NK
I1
D-J
NK
I1
D-J
NK
I1
D-J
NK
I1
10'5' 20' 30' 1h 5h
D-J
NK
I1
NMDA NMDA NMDA NMDA NMDA
D-J
NK
I1
D-J
NK
I1
D-J
NK
I1
D-J
NK
I1
control-MKK7control-MKK7
Cytoplasmic
NMDA-DAPI
DAPI
NMDA
D-J
NK
I1
Time-course of MKK7 with and without D-JNKI1
NMDA/D-JNKI1-MKK7 NMDA/D-JNKI1-MKK7
a b c
d e f
g h i j
k
 Quantification of MKK7
Nuclear
Nuclear
NMDA
D-JNKI1/NMDA
l
Cytoplasmic
D-JNKI1/NMDA
NMDA
0
500
1000
1500
2000
2500
Control NMDA
5'
NMDA
10'
NMDA
20'
NMDA
30'
NMDA
1h
NMDA
5h
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
Control NMDA
5'
NMDA
10'
NMDA
20'
NMDA
30'
NMDA
1h
NMDA
5h
R
at
io
 M
KK
7/
Tu
bu
lin
R
at
io
 M
KK
7/
Tu
bu
lin
Figure 5 MKK7 in excitotoxicity. Immunofluorescence study (a–j): after 1 h of 100mm of NMDA cortical neurons are stained with MKK7 antibody (a, b, c, h and i) and DAPI
(d, e, f, g and j). In the control condition, the labelling is punctate in the cell body (a), and sometimes nuclear (b, arrow). After 1 h of NMDA treatment, the staining becomes
almost exclusively nuclear (c, arrow). D-JNKI1 mostly prevents nuclear translocation (h, i) although if it is still possible to find neurons with nuclear labelling (i, arrow). Scale
bar, 10mm. Western blotting (k, l) of MKK7 following a NMDA time course on nuclear and cytoplasmic extracts of cortical neurons, in the presence or absence of D-JNKI1. In
control conditions, there is a pool of MKK7 in the cytoplasmic fractions and hardly any MKK7 is detectable in the nuclear fraction. After only 5 min NMDA treatment, cytoplasmic
MKK7 translocates into the nuclear fraction. D-JNKI1 prevents nuclear translocation and retains MKK7 in the cytoplasm (k, l). Results were similar in nine independent
experiments (7S.E.M.)
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JBD20 peptide powerfully prevented this interaction, whereas
the JBDmut
28 peptide had no effect. D-JNKI1 is known to block
JNK-mediated phosphorylation of IB1/JIP-1.8,9,28
We then investigated the neuroprotective effect of D-JNKI1
on IB1/JIP-1: it prevented 70% of its NMDA-induced decrease
and diminished the segregation into upper and lower
bands27,28 (Figure 7j).
Until now 35 sites of phosphorylation are known on IB1/
JIP1,29 but there is no specific phospho-antibody to study
JNK-mediated JIP-1 phosphorylation, which occurs at Thr-
103. To better assess changes in IB1/JIP-1 at 5 h of NMDA
and to verify the protective effect of D-JNKI1, we did a
proteomic analysis.
IB1/JIP-1 by proteomic analysis. In silver-stained two-
dimensional (2D) gels IB1/JIP-1 was barely detectable
(Figure 8a, see ring), but on 2D Western blots there was a
complex IB1/JIP-1 staining pattern (Figure 8b–d). Blots from
untreated neurons revealed up to six spots, showing that IB1/
JIP-1 exists in a variety of isoforms and undergoes several
post-translational modifications. The NMDA stimulus
resulted in a decrease of IB1/JIP-1 immunoreactivity and
the disappearance of the most acidic forms. A shift was
observed towards more basic proteins and also towards
forms of smaller Mw (suggesting a decrease in
phosphorylation). Pretreatment with D-JNKI1 reduced these
changes indicating that D-JNKI1 partially counteracts the
effects of the NMDA, probably by blocking the action of JNK
kinase on IB1/JIP-1.28,30 The counteracting effect of D-JNKI1
was confirmed when silver-stained 2D gels of control,
NMDA-stimulated and NMDA-stimulated D-JNKI1-treated
neurons were compared with the computer software
Melanie, using a heuristic clustering algorithm to classify
similar gels in the same group by comparing the similarity of
protein spots. The control gel and the NMDA plus D-JNKI1
inhibition gel were placed in the same group, confirming that
D-JNKI1 must counteract the effects of NMDA.
Discussion
In multiple nervous system acute pathological conditions,
including stroke and traumatic brain injury, overactivation of
NMDA receptors leads to neuronal injury, resulting in
neurological impairments. A treatment for these conditions
would have a massive impact in modern society and D-JNKI1
represents a new neuroprotective candidate for this aim. In
fact, the D-JNKI1 peptide is able to completely prevent
neuronal loss after NMDA treatment and to give powerful
protection against cerebral ischemia.6 However, the molecu-
lar mechanisms that modulate this powerful neuroprotection
remain partially unclear.
Excitotoxic neuronal death can show features of apoptosis
or necrosis (or a combination of the two,31 depending on the
duration and intensity of the insult and on the model
used2,32,33). In the present model involving cortical neurons
exposed to a high concentration of NMDA (100 mM), the
neuronal death has generally been described as necrotic
rather than apoptotic,31 and our present, albeit limited,
observations support this view. The neurons initially swelled
and presented strong staining with PI, with no clumped
chromatin. The fact that caspase-3 was activated shows that
apoptotic pathways were also activated, but the experiments
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Figure 6 MKK4 immunofluorescence (using 2nd antibody). After 1 h of 100mm
NMDA, cortical neurons are labeled with this MKK4 antibody (a, c and e) and
stained with DAPI (b, d and f). In the control condition (a), like after 1 h NMDA
stimulation (c), the labelling is equally distributed in both nuclei and cytoplasm.
D-JNKI1 pretreatment has no effect on MKK4 staining. Scale bar, 10 mm. Western
blotting (i) of MKK4 following an NMDA time course on cytoplasmic extracts of
cortical neurons in the presence or absence of D-JNKI1. NMDA reduced the MKK4
level, whereas D-JNKI1 strongly preserved it (i, j). Results were similar in six
independent experiments (7S.E.M.)
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with z-VAD.fmk and cycloheximide indicate that apoptotic
signalling was by no means the only contributor to cell death.
We analyzed NMDA-induced neuronal death from the initial
calcium entry to the effects on the JNK signalling pathway. We
examined the Caþ þ entry through NMDA receptor channels,
using imaging experiments with Fura-2, to see whether the D-
JNKI1 peptide interferes at the receptor level or further
downstream in the death cascade. The peptide did not change
Caþ þ influx, implying that D-JNKI1 did not protect at this
level, but more downstream.
In characterizing the NMDA-induced death pathway, we
found that z-VAD.fmk and cycloheximide alone were ineffec-
tive against NMDA toxicity, but combined they conferred 60%
protection on NMDA-treated cortical neurons at 24 h. This
suggests that NMDA activated at least two neuronal death
pathways: one is caspase-dependent and -independent of
protein synthesis and the other dependent on protein
synthesis. Interestingly, D-JNKI1 was neuroprotective even
in the presence of cycloheximide, implying that the neuro-
protection by D-JNKI1 affected both pathways. The action of
D-JNKI1 on c-jun and related transcription factors is well
known.6
Here, we focus our attention on the JNK targets which
contain a JBD homology sequence and whose phosphoryla-
tion by JNK is blocked by JBD20 at the concentration of 40 mM
in cell-free experiments.8,9 Among the JBD20-dependent
targets, four substrates (MADD/DENN, MKK4, MKK7 and
IB1/JIP-1) may be potentially implicated in the NMDA stress
response of cortical neurons.
These targets act at different levels in the JNK cascade.
MKK4 and MKK7 are upstream of JNK and are both activators
and substrates. In contrast, MADD and IB1/JIP1 are at a lower
level, downstream of JNK.
MADD/DENN. Our data suggest that post-translational
modification of MADD may be involved in the excitotoxic
process. NMDA stress caused a strong degradation of
MADD/DENN, and a nuclear translocation. This
degradation appears to be mediated by the ubiquitin
proteolytic pathway, as the two specific proteasome
inhibitors lactacystin and MG132 prevented it, whereas the
calpain inhibitor had no effect. D-JNKI1 prevented both
MADD degradation, as did the proteasome inhibitors, and
translocation inside the nucleus. Moreover, the JNK
competitive assay on MADD demonstrated that D-JNKI1
prevented the JNK-mediated phosphorylation of MADD.
Taken together, our data strongly suggest that inhibition of
JNK-mediated phosphorylation of MADD prevents its entry
into the proteasome pathway.
Thus, MADD/DENN post-translational modification may
represent an important component in excitotoxicity, but further
studies are needed to determine its role in the death process
and to determine the meaning of its phosphorylation and
translocation.
The two direct activators of JNK: MKK4 and MKK7. We
studied the localization and the contribution of these two JNK
activators in the response of JNK to excitotoxic stress. We
showed that already in the control condition the two kinases
present a different compartmentation in cortical neurons.
MKK7 is present in both nuclear and cytoplasmic
compartments, whereas MKK4 is confined to the
cytoplasm. Following NMDA stimulation, MKK7 strongly
translocated into the nuclei of dying neurons, whereas
MKK4 did not change its localization. In order to better
clarify the contribution of these two kinases to JNK activation
in excitotoxicity, we also analyzed MKK7 and MKK4
activation/phosphorylation in basal and stress conditions.
MKK7 showed a minor activation/phosphorylation in the
control condition, whereas after NMDA stimulation it was
quickly and powerfully activated. In fact, after 10 min of NMDA
stimulation MKK7 reached maximal activation, then dropped
back to the basal level in 1 h, as did JNK.
In contrast, the basal activity of MKK4 was elevated in the
control condition and did not respond with an increase in
phosphorylation after excitotoxic stress.
As D-JNKI1 selectively prevents inter-molecular inter-
actions between JNK and its JBD-containing targets, this
can result in an inhibition of MKK4 and MKK7 activity. At the
concentration (2 mM) used to prevent neuronal loss, we did not
detect any effects of D-JNKI1 on the activities of MKK4 and
MKK7, which was expected as we previously found no effect
on the activity of JNK.6 This suggests that the protective
effects of D-JNKI1 were due to its prevention of the activation
of its downstream targets (such as MADD) rather than to
inhibition of the feedback activation of MKK4 and MKK7. The
lack of effect of D-JNKI1 on the activities of MKK4 and MKK7
may be due to the fact that the concentration used in our
experiments (2mM) was too low compared to the concentra-
tion (40 mM) used in cell-free competitive assays where MKK7
and MKK4 phosphorylation is inhibited by JBD20.
8,9 The
significance of MKK4 and MKK7 phosphorylation by JNK is
not known, but it clearly constitutes a positive feedback loop in
the JNK cascade. Such feedback has been predicted to
explain the occurrence of bistability and ultrasensitivity in the
activation of JNK.34,35
Figure 7 IB1/JIP-1 in excitotoxicity. IB1/JIP-1 immunofluorescence study (a–f): after 1 h of 100mm NMDA cortical neurons are stained with IB1/JIP-1 antibody (a, c, e) and
DAPI (b, d, f). In the control condition, IB1/JIP-1 is localized in dendrites and axons (arrowhead) and in the soma of cortical neurons, including some nuclei (a). After NMDA, the
labelling becomes strongly nuclear (c, arrow) and the staining of neurites is limited (arrowhead). D-JNKI1 prevents nuclear translocation but does not preserve the labelling of
dendrites and axons (e). Scale bar, 10mm. Western blot study (g–h) of IB1/JIP-1 after a NMDA time course on total extracts (g) and fraction extracts (h) of cortical neurons.
IB1/JIP-1 level is stable from 5 min to 1 h of NMDA, but decreases clearly at 5 h, when two bands are visible (g). Fraction separation analysis confirms the immunofluorescence
data (h): in the control condition IB1/JIP-1 is distributed in both nuclear and cytoplasmic compartments, whereas after NMDA stimulation it increases in the nuclear fraction. In
vitro JNK-competitive assay with recombinant activated JNK3 (i), using GST-IB1/JIP-1 as substrate as described previously.5,6 The JBD20 peptide inhibits IB1/JIP-1
phosphorylation, whereas the control-mutated peptide JBDmut has no effect. Western blot study of D-JNKI1 effect on IB1/JIP-1 following NMDA: NMDA strongly reduces the
IB1/JIP-1 level and the D-JNKI1 strongly prevents it (j). Similar results were obtained in seven independent experiments (7S.E.M.)
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The scaffold protein IB1/JIP-1. IB1/JIP-1 under excitotoxic
stimuli altered its subcellular localization and accumulated in
the nuclei. A similar behavior was observed in hippocampal
neurons.20
We established that JNK participates actively in the
phosphorylation of IB1/JIP-1 and this consequently regulated
its stability. Exposure to NMDA stress induced a large
degradation of IB1/JIP-1. D-JNKI1 protected against NMDA-
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induced death by preventing IB1/JIP-1 phosphorylation and
degradation. In fact, having determined the effect of the
peptide in cell-free assays, we assume that D-JNKI1 blocks
JNK-mediated phosphorylation of IB1/JIP-18,9,28 and pre-
vents its degradation. We suggest here two possible roles for
the IB1/JIP-1 scaffold, in addition to its widely accepted linking
of the upstream signalling elements to JNK. First, it may play a
major role in directing the activated cascade into a particular
cellular compartment. Second, it may serve to ‘select’ some of
the downstream substrates of JNK. By blocking the action of
JNK on JBD20-dependent substrates, IB1/JIP-1 may be
promoting its access to the JBD20-independent ones.
MKK7 and MKK4 as potential targets for regulating the
JNK signalling pathway. It will be important to devise tools
(e.g. siMKK7 and siMKK4 or new specific cell-permeable
MKK7 and MKK4 inhibitor peptides) for preventing
selectively MKK7 and MKK4 activation with the aim of
determining the direct causality of JNK activation induced by
different stress stimuli.
Materials and Methods
Cortical neuronal culture. Small pieces of cortex were dissected from the
brains of 2-day-old rat pups, incubated with 200 U of papain for 30 min at 341C and
after trypsin inhibitor treatment (10 mg) were mechanically dissociated. Neurons
were then plated at densities of approximately 1 106 cells/plate on dishes
precoated with 25mg/ml poly-D-lysine. For immunocytochemistry, neurons were
plated at densities of 1 105 cells/coverslip on coverslips precoated with 50 mg/ml
poly-D-lysine and 20mg/ml laminin. The plating medium consisted of B27/
Neurobasal (Life Technologies, Gaithersburg, MD, USA) supplemented with
0.5 mM glutamine, 100 U/ml penicillin and 100mg/ml streptomycin. PI was used to
identify dying neurons at a concentration of 2 mg/ml, for 5 min immediately before
fixation. Experiments were performed after 11–13 days in culture, at which time the
neurons had elaborate axonal and dendritic arbors and had formed many synapses.
D-JNKI1 2 mM was added to the dishes 1 hour before NMDA treatment (100mM).
Cycloheximide (1 or 3mg/ml, fluka) and z-VAD.fmk (50, 150 or 300mM, Sigma-
Aldrich, St Louis, MO, USA) were added to the cultures 1 hour before NMDA. For
the degradation studies, the calpain inhibitor calpastatin was added at
concentrations of 5 and 10mM 60 min before the addition of NMDA. Different
concentrations of the proteasome inhibitors lactacystin and MG132 (10, 20mM)
were also added to the dishes 1 hour before NMDA treatment.
LDH cytotoxicity assay. Neuroprotection was evaluated by an LDH assay.
LDH released into the bathing medium 5–48 h after NMDA was measured using the
Cytotox 96 non-radioactive cytotoxicity assay kit (Promega, WI, USA).
Cytoplasmic and nuclear fractionation and total protein
extracts. After stimulation, cells were washed twice in ice-cold PBS þ 1 mM
MgCl2, and lysed for 10 min in lysis buffer
5 at 41C. Samples were then centrifuged at
900 g for 10 min at 41C to separate the supernatants (cytoplasmic fractions) from
the pellets (nuclear fractions).26 Nuclear pellets were washed once in the lysis buffer
and centrifuged at 900 g for 5 min at 41C, after which the pellets were
reconstituted in lysis buffer and sonicated. Samples were analyzed for protein
determination and equal proportions of nuclear and cytoplasmic fractions were
analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). Total protein extracts were obtained by scraping cells in lysis buffer.6
Western blot analysis. Proteins were separated by 10–14% SDS-PAGE and
transferred to a PVDF membrane. Incubation with primary antibodies was overnight
at 41C using: 1 : 10 000 anti-MKK7 (#M-86920, BD Transduction Laboratories, San
Jose, CA, USA), 1 : 1000 anti-P-MKK7 (a generous gift from Andreas H Nelsbach,
Cell Signaling Technology, Beverly, MA, USA), 1 : 5000 or 1 : 10 000 anti-MKK4
(#SC-964, Santa-Cruz Biotechnology, CA, USA and # 07-194 Upstate,
Charlottesville, VA, USA), 1 : 2000 anti-P-MKK4 (no. 9151 Cell Signaling
Technology, Beverly, MA, USA), 1 : 50 000 anti–IB1/JIP-1 (polyclonal IB1
antiserum was prepared against recombinant IB1 (aa 1280) and the antiserum
was subsequently affinity purified36), 1 : 5000 anti-MADD (a generous gift from Dr.
Ulrich Blank, INSERM U 699, Paris Cedex 18, France), 1 : 750 anti-caspase-3
antibody (#SC-1225 Santa-Cruz Biotechnology, CA, USA; which reacts with both
pro-caspase-3 and the cleaved p12 product). Both P-antibodies, P-MKK7 and P-
MKK4, are specific and recognize only the phosphorylated form of these proteins
(they do not recognize cortical neuronal extracts dephosphorylated with alkaline
phosphatase overnight). In a single experiment, a very large number of neurons
were analyzed, providing very consistent results, and the blots were all normalized
with respect to tubulin (#SC-8035 Santa-Cruz Biotechnology, CA, USA).
Immunoprecipitation. All steps were performed on ice. About 1 mg of cell
extract was incubated with an equivalent of 180mg Ig anti-P-MKK7 (see WB) or P-
MKK4 (#9156, Cell Signaling Technology, Beverly, MA, USA) for 30 min at 41C
under agitation. Protein A beads were added in the same tubes and samples were
incubated overnight at 41C. The immunoprecipitate was washed four times with
complete cold lysis buffer. The final pellet was dissolved in 40 ml 2
electrophoresis buffer, loaded into electrophoresis gels and transferred to a
PVDF membrane. To assess the activation of MKK4 and MKK7 compared to control
conditions, membranes were incubated overnight with the anti-non-phosphorylated
Figure 8 2D gels for IB1/JIP-1. Different samples are separated on 2D gels and
either stained by an ammoniacal silver method or immunostained after electric
transfer to nitrocellulose. Panel a is an example of a silver-stained gel of a control
samples. IB1/JIP-1 is barely visible (see the circle) in the 100 kD Mw region and
between pH 3 and 5. Only the specific areas of Western blots are shown (six spots)
from a control sample (b), after NMDA stimulation (c), or NMDA and D-JNKI1
exposure (d). The lower panels show the entire silver-stained gels for b, c and d.
The pH range of isoelectrophocusing is shown on top of the gels, and the molecular
weight range is indicated to the right. 2D gel results were obtained using pools of
three different dishes and in three independent experiments
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specific antibodies (MKK7: #559676, BD Pharmingen, San Jose, CA, USA; MKK4:
#07–194, Upstate, Charlottesville, VA, USA).
Quantification. The quantification of Western blots and immunoprecipitations
was performed using ImageQuant TL software (Amersham Biosciences) and was
based on at least five independent experiments.
Immunocytochemistry. All immunocytochemical reactions were performed
on cortical neurons plated on coverslips as described above. Cells were fixed in 4%
paraformaldehyde in PBS for 30 min, and then incubated for 1 h with 10% serum in
PBS-Triton 0.3%. Primary antibodies were diluted 1 : 200 (MKK7), 1 : 100 (MKK4,
#SC-964 Santa-Cruz Biotechnology, CA, USA), 1 : 500 (MADD), 1 : 1000 (IB/JIP-1)
in PBS-Triton 0.1% and incubated overnight at 41C. After washing in PBS, cells
were incubated with secondary fluorescein isothiocyanate (FITC)-anti mouse and
FITC-anti rabbit antibodies (FI-2000 and FI-1000, Vector Laboratories Inc.,
Burlingame, CA, USA), 1 : 200 in PBS for 1.5 h. Finally, coverslips were mounted in
Vectashield mounting medium for fluorescence with DAPI (H-1200, Vector
Laboratories Inc., Burlingame, CA, USA).
Kinase assays. Before initiating the kinase reactions, 2 mCi [g-33P]ATP and
40mM of peptides (JBD20 or JBDmut) were added to the activated recombinant
JNK2 or JNK3 (0.5mg, Upstate Biotechnology) for 15 min. Kinase reactions (Bonny
et al.,5) were performed for 30 min at 301C using 1mg of the GST-MADD or GST-
IB1/JIP-1 fusion proteins. Samples were then analyzed by SDS-PAGE and
autoradiography.
2D electrophoresis. Tissue was homogenized with 1:10 w/v IEF sample
buffer (5 M ureaþ 2 M thiourea 35 mM Trisþ 4% CHAPSþ 1% DTT, with a
protease inhibitor cocktail (Sigma p2714)) followed by a protein determination. First,
Zoom Strips pH 3–10, 8 cm long (ZOOM IPGRunner System, Invitrogen,
Switzerland) were rehydrated with 8 M urea, 2% CHAPS, 0.5% ampholytes pH
3–10, 0.02% bromphenolblue and 20 mM DTT was added just before the use. For
the second dimension, strips were incubated in equilibration buffer (6 M
ureaþ 1.5 M Tris-HCl pH 8.8þ 2% SDSþ 20% Glycerol v/v) with 200 mg DTT
per 10 ml buffer (buffer A) and 250 mg iodoacetamide per 10 ml buffer (buffer B).
Each channel was filled with buffer A for 15 min, and then buffer B for another
15 min. The second dimension was run on NuPage 4–12% Bis-Tris Zoom gel
(Invitrogen). Proteins were visualized by silver staining37 or transferred to
nitrocellulose. Gels were scanned with an Amersham Molecular Scanner and
results were analyzed with Melanie 4.0 software (Genebio, Geneva, Switzerland).
Microscopy for Ca2þi measurements. Experiments were carried out on
the stage of an inverted epifluorescence microscope (Carl Zeiss, Jena) and
observed through a 40 1.3 NA oil-immersion Neofluar objective lens (Zeiss).
Fluorescence excitation wavelengths were selected using a holographic
monochromator (Polychrome II, Till Photonics, Planegg, Germany) and
fluorescence was detected using a 12-bit cooled CCD camera (Micromax,
Princeton Instruments, Trenton, NJ, USA). Acquisition and digitization of images,
and time series were computer controlled using the software Metafluor (Universal
Imaging, West Chester, PA, USA) running on a Pentium computer. The acquisition
rate of ratio images was varied between 0.5 and 0.1 Hz. Once loaded with dye, cells
were placed in a perfusion chamber designed for rapid exchange of perfusion
solutions.38 Up to B25 individual neurons were simultaneously analyzed in the
selected field of view. Ca2þi was measured using Fura-2 (Molecular Probes,
Eugene, OR, USA) loaded into cells by incubation with 5 mM Fura-2 AM for 30 min at
371C. Experiments were run in CO2/bicarbonate-buffered solutions (NaCl 135, KCl
5.4, CaCl2 1.3, MgSO4 0.8, NaH2PO4 0.78, NaHCO3 25, glucose 5, glycine 3mM,
bubbled with 5% CO2/95% air). Calibration of cytoplasmic signal was accomplished
in situ at the end of some experiments as described previously.38 Fluorescence was
sequentially excited at 340 and 380 nm and detected at 4515 nm. Data are
presented as means7S.E.M. and Student’s t-test was used to assess statistical
significance.
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